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Conclusions: 1. A close follow-up policy
enables detection the second breast
cancer at an earlier stage than the primary
one. 2. SBBC and MBBC seem to be
different set of tumors in term of clinical
characteristics and survival.
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IL-15 INHIBITS SPONTANEOUS
APOPTOSIS OF CD4+ AND CD8+
PERIPHERAL BLOOD T
LYMPHOCYTES FROM PATIENTS
WITH MELANOMA
Osawa T., Kaczmarek A., Kowalczyk D.,
Bogusz-Osawa M., Mackiewicz A.
Department of Cancer Immunology,
Poznan School of Medical Sciences,
Wielkopolski Cancer Center, ul. Garbary 15,
61-866 Poznan, Poland
CD4+ and CD8+ T lymphocytes from the
peripheral blood of melanoma patients are
prone to undergo spontaneous apoptosis
when compared with healthy individuals.
The rapid lymphocyte turnover and the
loss of CD4+ and CD8+ T cells may cause
the weak antitumor response in cancer
patients. Since CD4+ and CD8+ T cell
mediated immune responses play an
important role in controlling the antitumor
response, enhancing the survival and
function of these T cells may improve the
disease outcome of melanoma patients. In
our experiment, we tried to see the effect
of interleukin 15 (IL-15) on the spon-
taneous apoptosis of peripheral blood
mononuclear cells (PBMCs) from patients
with melanoma. The PBMCs obtained
from 16 melanoma patients and 16 healthy
controls were incubated overnight in
medium with or without IL-15: The PBMCs
were then stained for CD4+ or CD8+ cells
and evaluated for apoptosis with the
Annexin V binding method using a
multicolor flow cytometry. The results
showed that IL-15 inhibits spontaneous
apoptosis in CD4+ and CD8+ T cells in
both melanoma patients and healthy
individuals. IL-15 significantly reduced
6.3% (mean±spontaneous apoptosis of
CD8+ T-cells in melanoma patients from
26 8.7% (n=16, P± SO) to 19 ±< 3.4%
to±0.005) and in healthy controls from 15
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3.4% (n=16, P±11 <0.005). There was a
similar result with CD4+ cells with 7.3%±
6.7% to 17 ±IL-15 reducing the apoptosis
in melanoma patients from 22 (n=16, P<
4.0% (n=16,± 4.1 % to 9 ±.005) and in
healthy controls form 12 P<.005). IL-15
may thus prove useful in a therapeutic
immunostimulation strategy for melanoma
patients
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FAS+ CD4+ AND FAS+ CD8+ CELLS
FROM THE PERIPHERAL BLOOD
OF MELANOMA PATIENTS PREFE-
RENTIALLY BIND ANNEXIN V
Osawa T., Kaczmarek A., Kowalczyk D.,
Bogusz-Osawa M., Mackiewicz A.
Department of Cancer Immunology,
Poznan School of Medical Sciences,
Wielkopolski Cancer Center, ul. Garbary 15,
61-866 Poznan, Poland
Malignant melanoma is resistant, except
for a small percent, to treatments such as
radio and chemotherapy. On the other
hand melanoma has been considered as
the prototypical immunogenic tumor in
which the immune system may have a role
in the outcome of the disease. Immune
cells from cancer patients respond poorly
to mitogenic or antigenic stimuli. One
reason for this is the rapid turn over of the
T lymphocytes arising from the apoptosis
of these cells. The induction of apoptosis
in the activated T lymphocytes is
considered as one of the ways the tumor
cells avoid recognition and destruction.
The Fas (APO-1, CD95)/FasL pathway is
well know to induce apoptotic cell death
in many cells. In this study the expression
of Fas and its correlation withapoptosis
on CD4+ and CD8+ T cells in PBMCs from
melanoma patients was measured.
Annexin V was used to measure apo-
·ptosis. For the present study, we obtained
5ml of venous blood from 16 pa-tients and
10 healthy controls. The lymphocytes were
then isolated using the Ficoll-Hypaque
gradient centrifugation. The lymphocytes
were then incubated in medium for 24hrs
and then stained with PerCP-labled
monoclonal antibodies of anti CD4 or anti
CD8. They were then washed and stained
S299
with PE labeled CD95 antibody. The cells
were then washed and stained with
Annexin V FITC. The cells were then
measured using a three color flow
cytometer. The correlation between the
CD4+ Annexin V+ and CD4+ Fas+
Annexin V+ for patients was r=0.84 and for
controls was r=0.81. For CD8+ a similar
result was obtained with CD8+ Annexin V+
and CD4+ Annexin V+ Fas+ was r=0.82
for patients and r=0.78 for controls. The
Fas/FasL pathway may not be the only
mechanism responsible for the increased
apoptosis of CD4+ and CD8+ cells but the
contribution is significant.
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TREATMENT OF MELANOMA
PATIENTS WITH GENETICALLY
MODIFIED TUMOR VACCINES
(GMTV) DOES NOT DECREASE
THE SPONTANEOUS APOPTOSIS
OF CD4+ AND CD8+ T CELLS
Osawa T., Kaczmarek A.,Kowalczyk D.,
Bogusz-Osawa M., Mackiewicz A.
Department of Cancer Immunology,
Poznan School of Medical Sciences,
Wielkopolski Cancer Center, ul. Garbary 15,
61-866 Poznan, Poland
In this study, the spontaneous apoptosis
of CD4+ and CD8+ T-cells in patients with
melanoma were examined. Fifty-seven
patients enrolled in the study were partici-
pating in an experimental immunotherapy
study and were administered vaccines
consisting of irradiated, gene modified
allogenic melanoma cells: MICH I H6/
GMCSF + MICH II H6/GMCSF. The con-
trol group consisted. of 20 healthy volun-
teers. Venous blood was obtained on the
day of the administration of the first
vaccine, and then approximately once a
month. Blood was obtained in EDTA
tubes, after which the lymphocytes were
isolated by Ficoll-Hypaque gradient
centrifugation. The lymphocytes were then
incubated for 24hrs in medium containing
fetal calf serum at 3rC in 5% C02 to
allow for spontaneous apoptosis to take
place. The lymphocytes were then stained
with PE-Iabeled CD4 or CD8 and next,
stained for apoptosis using the FITC-
S300
labeled Annexin V binding method. A two
color flow cytometry was used to measure
the proportion of CD4+ and CD8+
lymphocytes that underwent apoptosis.
SD) of CD4+ T cells were Annexin±6.3%
(mean ±In patients with melanoma 21
6.3% in healthy controls (P±V+ compared
with 15 < 0.0001). For CD8+ T cells,
4.5%±8.1 % of T cells were Annexin V+
and in healthy controls 19±in patients 31 of
T cells were Annexin V+(P < 0.0001).
There were no significant changes with
time in the proportion of CD4+ and CD8+
lymphocytes undergoing spontaneous
apoptosis after the start of the gene
modified tumor vaccine therapy.
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ANALIZA CYTOGENETYCZNA
W DIAGNOSTYCE NIEZIARNICZYCH
CHt.ONIAKOW B-KOMORKOWYCH
(B-NHL)
Pienkowska-Grela B.
Centrum Onkologii - Instytut, Warszawa
Poznanie molekularnych mechanizmow
patogenezy i rozwoju chtoniakow nieziar-
niczych przyniosto intensywny post~p
w metodach diagnozowania B-NHL.
Obecnie stosowana klasyfikacja chorob
rozrostowych uktadu chtonnego REAU-
WHO oparta jest na analizie danych
morfologicznych, immunofenotypowania
oraz badan cytogenetycznych i moleku-
larnych, pozwalajqcych na okreslenie
genetycznych nieprawidtowosci wyst~pu­
jqcych w komorkach nowotworu. Istotq
badania cytogenetycznego jest okreslenie
odst~pstw od prawidtowego kariotypu
w komorkach nowotworu. Obok klasycz-
nych metod prqzkowych, stosowane Sq
techniki FISH (fluorescent in situ hybridi-
zation) umozliwiajqce, przy ui:yciu specy-
ficznych sond DNA, precyzyjne okreslenie
zmian obejmujqcych poszczegolne chro-
mosomy, ich cz~sci bqdi: okreslone geny.
Aberracje wyst~pujqce w komorkach chto-
niakow, to przede wszystkim translokacje,
ktorych efektem jest deregulacja ekspresji
okreslonych biatek. W wyniku p~kni~cia
chromosomu i przeniesienia jego frag-
mentu nast~puje zaburzenie funkcjono-
wania genow znajdujqcego si~ w uszko-
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